FDA Approves First Biosimilar Drug

On Friday, March 6, the Food and Drug Administration approved the first biosimilar drug for use in the United States. Zarxio, produced by Sandoz and used to prevent infections in cancer patients who are receiving chemotherapy, is a close copy of Neupogen, a biologic drug produced by Amgen. Zarxio was approved under the Biologics Price Competition and Innovation Act of 2009, part of the 2010 Patient Protection and Affordable Care Act. This 2009 law created a pathway to market for biologic products demonstrated to be highly similar, or biosimilar, to an existing FDA-approved biologic drug.

Biologics are derived from living cells and produced through more complicated processes than those used for traditional brand-name and generic drugs. Biosimilars have the potential to produce cost savings and improve patient access to needed medications. Although they are not identical to biologics, there is no clinically meaningful difference between them. In a news release, FDA Commissioner Margaret A. Hamburg, M.D., said, “Patients and the health care community can be confident that biosimilar products approved by the FDA meet the agency’s rigorous safety, efficacy, and quality standards.”

Biosimilars have been available in Europe for the past decade, where their accessibility has led to lower prices for some biologics. Pew’s specialty drugs research initiative is exploring policies that could lead to similar savings in the United States. 

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Article

37 Scientists Pioneering the Future of Biomedical Research

Quick View
Article

Biomedical researchers are at the heart of nearly every medical advancement. From cutting-edge cancer treatments to breakthrough discoveries about emerging viruses, these scientists use creativity and ingenuity to explore new horizons in human health and medicine. And for nearly 40 years, The Pew Charitable Trusts has supported more than 1,000 early-career researchers committed to this work.

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?